Email ID
Password
Scrip   
Boehringer and Priaxon sign €86 million anticancer pact
18 January 2010
Christopher Spillane

Boehringer Ingelheim and Priaxon have agreed to develop mdm2/p53 inhibitors for the treatment of cancer in a €86 million deal.

P53 is a human tumour suppressor protein and is necessary for the control of a cell's cycle. Loss of p53 function is involved in about 50% of human cancers....



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36